AZN
AstraZeneca PLC · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.1% · net new positions -4.2% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 3.19M | $514.55M | n/a | −2 |
| Q2 2026 | 154 | +6 | 584.53M | $109.90B | +11 | −6 |
| Q1 2026 | 151 | +2 | 571.10M | $111.81B | +21 | −20 |
| Q4 2025 | 148 | 0 | 438.95M | $40.35B | +2 | −1 |
| Q3 2025 | 24 | 0 | 219.30M | $16.82B | +1 | −2 |
| Q2 2025 | 22 | -1 | 189.68M | $13.26B | n/a | −1 |
| Q1 2025 | 21 | 0 | 171.06M | $12.57B | n/a | n/a |
| Q4 2024 | 21 | +3 | 174.28M | $11.42B | +3 | n/a |
| Q3 2024 | 17 | -3 | 166.39M | $12.97B | n/a | −3 |
| Q2 2024 | 20 | n/a | 172.48M | $13.45B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 49.12M | -5.4% | $3.77B | 0.4% | ▼ Trim | 6 | SEC ↗ ×2 |
| 2 | PRIMECAP Management ✦ | 39.86M | -3.3% | $3.06B | 2.3% | ▼ Trim | 6 | SEC ↗ |
| 3 | Wellington Management ✦ | 32.30M | -5.9% | $2.48B | 0.4% | ▼ Trim | 6 | SEC ↗ ×7 |
| 4 | Fidelity (FMR) ✦ | 21.69M | +1.6% | $1.66B | 0.1% | ▲ Add | 2 | SEC ↗ ×6 |
| 5 | Fisher Asset Management ✦ | 21.16M | +2.3% | $1.62B | 0.6% | ▲ Add | 6 | SEC ↗ |
| 6 | Goldman Sachs Group ✦ | 13.67M | n/a | $1.05B | 0.2% | n/c | 1 | SEC ↗ ×6 |
| 7 | Morgan Stanley ✦ | 13.45M | n/a | $1.03B | 0.1% | n/c | 1 | SEC ↗ ×15 |
| 8 | JPMorgan Chase ✦ | 9.65M | n/a | $740.21M | 0.0% | n/c | 1 | SEC ↗ ×34 |
| 9 | BlackRock ✦ (passive) | 5.80M | +5.8% | $445.31M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 10 | Citadel Advisors ✦ | 3.59M | +95.9% | $275.14M | 0.2% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 2.23M | +94.6% | $170.88M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 12 | Capital World Investors ✦ | 1.09M | +612.2% | $83.50M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | State Street Global Advisors ✦ (passive) | 967.15K | +3.0% | $74.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 849.70K | -26.5% | $65.19M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | Marshall Wace ✦ | 696.49K | -65.2% | $53.44M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 16 | Adage Capital Partners ✦ | 672.94K | +106.8% | $51.63M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 17 | Point72 Asset Management ✦ | 569.37K | -66.2% | $43.68M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 517.70K | -39.7% | $39.72M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passive) | 503.47K | -0.3% | $38.63M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Bridgewater Associates ✦ | 462.86K | -25.4% | $35.51M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 231.63K | -87.8% | $17.77M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 22 | Dodge & Cox ✦ | 137.49K | 0.0% | $10.55M | 0.0% | Held | 6 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 84.78K | +57.2% | $6.50M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 24 | Gotham Asset Management ✦ | 2.74K | New | $209,983 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Gotham Asset Management | $209,983 | 0.0% |
Exited
| Renaissance Technologies | $91.11M | was 0.1% |
| Norges Bank | $4.22M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,307 holders, 729.50M shares, $139.69B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · See Remarks · 20 sh @ 160.57 · $3,249
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology